Cyclacel Pharmaceuticals (CYCC)
(Delayed Data from NSDQ)
$0.98 USD
-0.04 (-3.92%)
Updated Sep 20, 2024 04:00 PM ET
After-Market: $0.98 0.00 (0.00%) 7:58 PM ET
2-Buy of 5 2
F Value A Growth C Momentum C VGM
Brokerage Reports
Cyclacel Pharmaceuticals, Inc. [CYCC]
Reports for Purchase
Showing records 1 - 20 ( 79 total )
Company: Cyclacel Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
Company: Cyclacel Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
2Q24: Interim Phase 2 Fadraciclib Data Coming in 4Q24
Provider: Roth Capital Partners, Inc.
Analyst: ASCHOFF J
Company: Cyclacel Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
Company: Cyclacel Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
ASCO Presentation Reveals Final Phase 1 Fadraciclib Data And RP2D
Provider: Roth Capital Partners, Inc.
Analyst: ASCHOFF J
Company: Cyclacel Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
Company: Cyclacel Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
Specifies Fadraciclib Patient Targeting, Reformulating Plogosertib
Provider: Roth Capital Partners, Inc.
Analyst: ASCHOFF J
Company: Cyclacel Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
Biotechnology - 36th Annual Roth Conference, Biotechnology Track, March 17-19
Provider: Roth Capital Partners, Inc.
Analyst: ASCHOFF J
Company: Cyclacel Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
Company: Cyclacel Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
Fadraciclib Shows Efficacy Against CDKN2A, CDKN2B, MTAP Deletion Tumors
Provider: Roth Capital Partners, Inc.
Analyst: ASCHOFF J
Company: Cyclacel Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
Company: Cyclacel Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
3Q23: Progress and Positive Clinical Results Defy Sub-Cash Valuation
Provider: Roth Capital Partners, Inc.
Analyst: ASCHOFF J
Company: Cyclacel Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
Progress and Positive Clinical Results Defy Sub-Cash Valuation
Provider: Roth Capital Partners, Inc.
Analyst: ASCHOFF J
Company: Cyclacel Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
Company: Cyclacel Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
4Q22: Delivery of Encouraging Clinical Results Defies Sub-Cash Valuation
Provider: Roth Capital Partners, Inc.
Analyst: ASCHOFF J
Company: Cyclacel Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
Company: Cyclacel Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
3Q22: Positive Phase 1 Solid Tumor/Lymphoma Data with Fadraciclib & CYC140
Provider: Roth Capital Partners, Inc.
Analyst: ASCHOFF J
Company: Cyclacel Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
Company: Cyclacel Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
Company: Cyclacel Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
R&D Day Takeaways Regarding Fadraciclib And CYC140
Provider: Roth Capital Partners, Inc.
Analyst: ASCHOFF J